CSC(601066) 中国经济网·2024-11-24 09:01Core Viewpoint - Shengda Biotech has received approval from the Shanghai Stock Exchange's Listing Review Center for its application to issue shares to specific investors, pending final approval from the China Securities Regulatory Commission (CSRC) [1][2]. Group 1: Issuance Details - The company plans to raise a total of no more than 267.61 million yuan (approximately 26.76 million) through this issuance, with the funds intended for a project to produce 20,000 tons of D-isoascorbic acid and its sodium salt [3]. - The issuance will target no more than 35 specific investors who meet the CSRC's criteria, with the final issuance price to be determined after obtaining approval from the Shanghai Stock Exchange and the CSRC [4]. - The maximum number of shares to be issued is 51,356,687, which will not exceed 30% of the company's total share capital prior to the issuance [4]. Group 2: Shareholding Structure - As of the date of the fundraising prospectus, Shengda Group is the controlling shareholder, holding 45,375,792 shares, accounting for 26.51% of the total shares [4]. - After the issuance, Shengda Group's shareholding is projected to decrease to 20.39%, while the actual controller, Hong Ai, will still indirectly control 40.52% of the company's shares, indicating that the control of the company will not change [5]. Group 3: Underwriting Information - The lead underwriter for this issuance is CITIC Securities Co., Ltd., with representatives Wang Zhan and Wang Shuyan [6].